Cynapsus Therapeutics Inc. : Cynapsus Therapeutics Announces Change of Auditor
(Thomson Reuters ONE) -
PRESS RELEASE
Cynapsus Therapeutics Announces Change of Auditor
September 19, 2014
TORONTO - Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company") (TSX-V: CTH)
(OTCQX: CYNAF) announces that it has changed its auditor. McGovern, Hurley,
Cunningham, LLP (the "Former Auditor") has resigned at the request of the
Company, effective September 18, 2014. The Directors of the Company have
appointed Ernst & Young LLP (the "Successor Auditor") of Toronto, Ontario as
auditor for the Company, effective September 19, 2014 until the close of the
Company's next Annual General Meeting. The change in auditor has been approved
by Cynapsus' Audit Committee and Board of Directors.
There were no reservations in the Former Auditor's reports in connection with
the two most recently-completed fiscal years or for any period subsequent to the
most recently-completed period for which an audit report was issued and
preceding the date of the Former Auditor's resignation. There are no reportable
events between Cynapsus and the Former Auditor as defined in National Instrument
51-102 - Continuous Disclosure Obligations.
About Cynapsus Therapeutics
Cynapsus is a specialty pharmaceutical company developing a convenient and easy
to use sublingual (oral) thin film strip for the acute rescue of OFF motor
symptoms of Parkinson's disease. Cynapsus' drug candidate, APL-130277, is an
easy-to-administer, fast-acting reformulation of apomorphine, which is the only
approved drug (in the United States, Europe, Japan and other countries) to
rescue patients from OFF episodes. Cynapsus is focused on maximizing the value
of APL-130277 by completing pivotal studies in advance of a New Drug Application
("NDA") expected to be submitted in 2016.
Over one million people in the U.S. and an estimated 4 to 6 million people
globally suffer from Parkinson's disease. Parkinson's disease is a chronic and
progressive neurodegenerative disease that impacts motor activity, and its
prevalence is increasing with the aging of the population. Based on a recent
study and the results of the Corporation's Global 500 Neurologists Survey, it is
estimated that between 25 percent and 50 percent of patients experience OFF
episodes in which they have impaired movement or speaking capabilities. Current
medications only control the disease's symptoms, and most drugs become less
effective over time as the disease progresses.
More information about Cynapsus (TSX-V: CTH) (OTCQX: CYNAF) is available at
www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval
(SEDAR) at www.sedar.com.
Contact Information
Cynapsus Therapeutics
Anthony Giovinazzo
President and CEO
(416) 703-2449 x225
ajg(at)cynapsus.ca
Andrew Williams
COO & CFO
(416) 703-2449 x253
awilliams(at)cynapsus.ca
Forward Looking Statements
This announcement contains "forward-looking statements" within the meaning of
applicable securities laws. Generally, these forward-looking statements can be
identified by the use of forward-looking terminology such as "plans", "expects"
or "does not expect", "is expected", "budget", "scheduled", "estimates",
"forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or
variations of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might" or "will be taken", "occur" or "be
achieved". Forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results, level of
activity, performance or achievements of Cynapsus to be materially different
from those expressed or implied by such forward-looking statements, including
but not limited to those risks and uncertainties relating to Cynapsus' business
disclosed under the heading "Risk Factors" in its March 26, 2014, Annual
Information Form and its other filings with the various Canadian securities
regulators which are available online at www.sedar.com.
Although Cynapsus has attempted to identify important factors that could cause
actual results to differ materially from those contained in forward-looking
statements, there may be other factors that cause results not to be as
anticipated, estimated or intended. There can be no assurance that such
statements will prove to be accurate, as actual results and future events could
differ materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward-looking statements. Cynapsus
does not undertake to update any forward-looking statements, except in
accordance with applicable securities laws.
Neither the TSX Venture Exchange nor the OTCQX International has approved or
disapproved of the contents of this press release.
--30--
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cynapsus Therapeutics Inc. via GlobeNewswire
[HUG#1856998]
Unternehmensinformation / Kurzprofil:
Datum: 19.09.2014 - 14:00 Uhr
Sprache: Deutsch
News-ID 341873
Anzahl Zeichen: 5886
contact information:
Town:
Toronto
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 134 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cynapsus Therapeutics Inc. : Cynapsus Therapeutics Announces Change of Auditor"
steht unter der journalistisch-redaktionellen Verantwortung von
Cynapsus Therapeutics Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
